Bayer Stock - long-term strategy under new CEO Anderson

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 10:15 CET. Details in the imprint.

Bayer (DE000BAY0017) is deep in a strategic overhaul under CEO Bill Anderson as the group seeks to stabilize its balance sheet and focus its businesses for long-term growth. Management has outlined a multiyear efficiency and portfolio strategy while continuing to work through litigation overhangs according to recent company statements.

Bayer's current strategic overhaul

Bayer has been pursuing a broad transformation program since CEO Bill Anderson took over in 2023, focused on simplifying the organization, cutting costs and improving cash generation. The company has flagged a multibillion-euro efficiency effort and a flatter management structure.

Management has also repeatedly emphasized that capital allocation is centered on deleveraging after the Monsanto acquisition, sustaining key R&D projects and carefully evaluating portfolio options. This includes ongoing reviews of non-core assets in both the pharma and crop science divisions.

Long-term focus on pharma and crop science

Strategically, Bayer continues to focus on its two main pillars: innovative pharmaceuticals and crop science inputs, including seeds and crop protection products. In pharma, the company is working to offset patent expiries with new launches in areas such as cardiology and oncology.

In crop science, Bayer aims to leverage its strong positions in herbicides and seeds, while investing in digital farming solutions that promise more precise and sustainable agriculture. These investments are framed as key long-term growth drivers despite near-term market volatility.

How the company makes money

Bayer generates most of its revenue from prescription medicines, crop protection chemicals, seeds and traits, and over-the-counter health brands, with Europe and North America as key markets. Earnings are heavily influenced by patent cycles in pharma and agricultural commodity trends.

Where the stock trades today

The shares of Bayer (DE000BAY0017) trade on Xetra at EUR 37.81 as of 06/19/2026, 10:10 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.